+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antifibrinolytic Drugs Market by Drug Type, Route Of Administration, Application, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Antifibrinolytic Drugs Market by Drug Type, Route Of Administration, Application, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Antifibrinolytic Drugs Market by Drug Type, Route Of Administration, Application, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015084
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antifibrinolytic Drugs Market grew from USD 15.47 billion in 2023 to USD 16.17 billion in 2024. It is expected to continue growing at a CAGR of 5.04%, reaching USD 21.84 billion by 2030.

Antifibrinolytic drugs, essential in managing excessive bleeding by preventing the breakdown of fibrin clots, play a vital role in healthcare. The necessity of these drugs derives from their application in surgeries, trauma care, and conditions like hemophilia, where controlling hemorrhage is paramount. This market's scope spans across hospitals, surgical centers, and specialty clinics, with end-use extending to individual patients who require long-term management of bleeding disorders. The market is primarily driven by increased surgical procedures, the rise in prevalence of bleeding disorders, and the growing awareness regarding timely medical intervention. An emerging opportunity lies in developing novel drug formulations that increase efficacy while reducing side effects, such as targeted delivery systems that minimize systemic exposure. Additionally, expanding into underserved regions with less access to bleeding management interventions represents a significant growth opportunity. However, market growth is challenged by stringent regulatory approvals, the high cost of advanced medications, and potential adverse effects, which can deter use. Research and innovation should focus on enhancing drug stability, reducing adverse reactions, and exploring combination therapies to improve patient outcomes. The market exhibits a dynamic nature, influenced by ongoing R&D and advancements in medical technologies. Key areas for innovation include the development of biosimilars to reduce costs and extend access, and the integration of antifibrinolytic therapies with personalized medicine approaches, using patient-specific data to tailor treatments. Companies should also invest in comprehensive clinical trials to establish safety and efficacy profiles that meet global standards, paving the way for broader acceptance and market penetration. To capture these opportunities, strategic partnerships and collaborations between pharmaceutical firms and research institutions are recommended, fostering innovation and expanding the market footprint.

Understanding Market Dynamics in the Antifibrinolytic Drugs Market

The Antifibrinolytic Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of bleeding disorders significantly driving antifibrinolytic drugs market demand
    • Growing awareness and availability of advanced antifibrinolytic treatments boosting market growth
    • Government initiatives and funding for healthcare infrastructure supporting antifibrinolytic drug market expansion
    • Rising adoption of antifibrinolytic drugs in surgical procedures enhancing market opportunities
  • Market Restraints
    • Adverse side effects leading to decreased patient compliance and drug discontinuation rates
    • Increasing availability and preference for alternative therapeutic options hindering market growth
  • Market Opportunities
    • Expansion of antifibrinolytic drug applications in traumaand emergency care
    • Growing adoption of antifibrinolytic drugs in dental surgery and procedures
    • Increasing use of antifibrinolytic drugs in chronic liver disease management
  • Market Challenges
    • Limited awareness among healthcare providers about the benefits of antifibrinolytic drugs in various treatments
    • The challenge of integrating antifibrinolytic drugs into established clinical practice guidelines and protocols

Exploring Porter’s Five Forces for the Antifibrinolytic Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Antifibrinolytic Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antifibrinolytic Drugs Market

External macro-environmental factors deeply influence the performance of the Antifibrinolytic Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antifibrinolytic Drugs Market

The Antifibrinolytic Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antifibrinolytic Drugs Market

The Antifibrinolytic Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Antifibrinolytic Drugs Market

The Antifibrinolytic Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antifibrinolytic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, CSL Behring LLC., Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Informa PLC, Johnson & Johnson Services, Inc., Leo Pharma A/S, Merck & Co., Inc., Novartis AG, Pfizer Inc., Portola Pharmaceuticals, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Antifibrinolytic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Aminocaproic Acid
    • Aprotinin
    • Tranexamic Acid
  • Route Of Administration
    • Injectable
    • Oral
    • Topical
  • Application
    • Hemophilia
    • Menorrhagia
    • Nosebleeds
    • Surgery
      • Cardiac Surgery
      • Neurological Surgery
      • Orthopedic Surgery
      • Other Surgeries
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of bleeding disorders significantly driving antifibrinolytic drugs market demand
5.1.1.2. Growing awareness and availability of advanced antifibrinolytic treatments boosting market growth
5.1.1.3. Government initiatives and funding for healthcare infrastructure supporting antifibrinolytic drug market expansion
5.1.1.4. Rising adoption of antifibrinolytic drugs in surgical procedures enhancing market opportunities
5.1.2. Restraints
5.1.2.1. Adverse side effects leading to decreased patient compliance and drug discontinuation rates
5.1.2.2. Increasing availability and preference for alternative therapeutic options hindering market growth
5.1.3. Opportunities
5.1.3.1. Expansion of antifibrinolytic drug applications in traumaand emergency care
5.1.3.2. Growing adoption of antifibrinolytic drugs in dental surgery and procedures
5.1.3.3. Increasing use of antifibrinolytic drugs in chronic liver disease management
5.1.4. Challenges
5.1.4.1. Limited awareness among healthcare providers about the benefits of antifibrinolytic drugs in various treatments
5.1.4.2. The challenge of integrating antifibrinolytic drugs into established clinical practice guidelines and protocols
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Antifibrinolytic Drugs Market, by Drug Type
6.1. Introduction
6.2. Aminocaproic Acid
6.3. Aprotinin
6.4. Tranexamic Acid
7. Antifibrinolytic Drugs Market, by Route Of Administration
7.1. Introduction
7.2. Injectable
7.3. Oral
7.4. Topical
8. Antifibrinolytic Drugs Market, by Application
8.1. Introduction
8.2. Hemophilia
8.3. Menorrhagia
8.4. Nosebleeds
8.5. Surgery
8.5.1. Cardiac Surgery
8.5.2. Neurological Surgery
8.5.3. Orthopedic Surgery
8.5.4. Other Surgeries
9. Antifibrinolytic Drugs Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Clinics
9.4. Hospitals
10. Antifibrinolytic Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Americas Antifibrinolytic Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antifibrinolytic Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antifibrinolytic Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTIFIBRINOLYTIC DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTIFIBRINOLYTIC DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ANTIFIBRINOLYTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ANTIFIBRINOLYTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIFIBRINOLYTIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTIFIBRINOLYTIC DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY AMINOCAPROIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APROTININ, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY TRANEXAMIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY MENORRHAGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY NOSEBLEEDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY CARDIAC SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY NEUROLOGICAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY OTHER SURGERIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 56. CANADA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. CANADA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. MEXICO ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. CHINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. CHINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. CHINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. CHINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 88. CHINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. CHINA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. INDIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. INDIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. INDIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. INDIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 94. INDIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. INDIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. JAPAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. JAPAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. JAPAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. JAPAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 106. JAPAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. JAPAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. THAILAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. THAILAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. THAILAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. THAILAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 142. THAILAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. THAILAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. DENMARK ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. DENMARK ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. DENMARK ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 161. DENMARK ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. DENMARK ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. EGYPT ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 164. EGYPT ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. EGYPT ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. EGYPT ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 167. EGYPT ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. EGYPT ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. FINLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. FINLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 173. FINLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. FINLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. FRANCE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. FRANCE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. FRANCE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. FRANCE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. FRANCE ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. GERMANY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. GERMANY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 185. GERMANY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. GERMANY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. ITALY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. ITALY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. ITALY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. ITALY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 197. ITALY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. ITALY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. NORWAY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. NORWAY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 215. NORWAY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. NORWAY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. POLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. POLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. POLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. POLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 221. POLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. POLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. QATAR ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. QATAR ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. QATAR ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. QATAR ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 227. QATAR ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. QATAR ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. SPAIN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. SPAIN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. SPAIN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 251. SPAIN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. SPAIN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. TURKEY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. TURKEY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. TURKEY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. TURKEY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 269. TURKEY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. TURKEY ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM ANTIFIBRINOLYTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. ANTIFIBRINOLYTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. ANTIFIBRINOLYTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Antifibrinolytic Drugs Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Alcon Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CSL Behring LLC.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Informa PLC
  • Johnson & Johnson Services, Inc.
  • Leo Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 16.17 Billion
Forecasted Market Value ( USD ) by 2030 $ 21.84 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Antifibrinolytic Drugs Market Report by Indication (Gynecology, Hereditary Angioedema, Fibrinolytic Response Testing, Surgeries, and Others), Form (Oral, Injectable), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Trauma Centers, and Others), and Region 2024-2032 - Product Image

Antifibrinolytic Drugs Market Report by Indication (Gynecology, Hereditary Angioedema, Fibrinolytic Response Testing, Surgeries, and Others), Form (Oral, Injectable), End User (Hospitals and Clinics, Ambulatory Surgical Centers, Trauma Centers, and Others), and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Antifibrinolytic Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Antifibrinolytic Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 74 Pages
  • Global
From
Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2024-2032 - Product Image

Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2024-2032

  • Report
  • 141 Pages
  • Global
From
Hemophilia Treatment Market by Product Type, Disease Indication, Distribution - Global Forecast 2025-2030 - Product Image

Hemophilia Treatment Market by Product Type, Disease Indication, Distribution - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Bleeding Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

Bleeding Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From

About the Antifibrinolytic Market

Antifibrinolytic drugs are a class of hematological drugs used to reduce the breakdown of blood clots. They are used to treat and prevent excessive bleeding in a variety of conditions, including hemophilia, trauma, surgery, and childbirth. Antifibrinolytics work by inhibiting the activity of plasmin, an enzyme that breaks down fibrin, the main component of blood clots. This helps to stabilize the clot and reduce bleeding. Common antifibrinolytic drugs include tranexamic acid, aminocaproic acid, and epsilon aminocaproic acid. The antifibrinolytic market is a growing segment of the hematological drugs market. It is driven by the increasing prevalence of bleeding disorders, the growing demand for minimally invasive surgeries, and the increasing use of antifibrinolytics in obstetrics and gynecology. Some companies in the antifibrinolytic market include Pfizer, Novartis, Bayer, Sanofi, and Merck. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.